Industry Overview - The Chinese medicine industry is entering a new evidence-driven cycle following the release of the Basic Drug Directory Management Measures, which emphasizes the integration of clinical value, insurance payment capabilities, and tiered diagnosis and treatment systems [8][10] - The market performance of the Chinese medicine sector showed a decline of 1.75% in the week before the holiday, which was the largest drop among the pharmaceutical sub-sectors [3][4] Market Performance - The Chinese medicine sector's PE (ttm) was 27X, down 0.49X from the previous period, while the PB (lf) was 2.27X, down 0.04X, indicating a relative valuation position within historical ranges [5] - The overall pharmaceutical sector index closed at 8282.27 points, down 0.81%, with only the medical services sector showing an increase of 0.22% [3] Upstream Market Dynamics - The market demand for Chinese medicinal materials has increased ahead of the holiday, leading to a slight rise in the price index, which reached 229.02 points, up 0.1% from the previous week [6][7] Regulatory Changes - The revised Basic Drug Directory Management Measures highlight a "balanced approach to Chinese and Western medicine," establishing a strict negative list for market entry and emphasizing clinical value and dynamic adjustments [9] - The new measures are expected to accelerate structural differentiation in the short term and favor leading companies with clinical evidence and strong innovation capabilities in the long term [8][10] Investment Recommendations - The report maintains an "overweight" rating for the industry, suggesting three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Price governance will lead to clearer differentiation within the industry, with companies that have competitive advantages likely to benefit from price-volume trade-offs [12] - The recovery of consumption driven by macroeconomic improvement and increased health awareness among the aging population is expected to boost sales of consumer-oriented Chinese medicines [13] - State-owned enterprises in the Chinese medicine sector are anticipated to benefit from reforms aimed at improving efficiency and performance [13] Target Companies - Recommended companies include Zoli Pharmaceutical and Yiling Pharmaceutical, with a focus on those with strong R&D capabilities and unique products, as well as those less affected by centralized procurement [13]

Core Viewpoint - The recent performance of the Chinese medicine sector, particularly the Chinese Medicine ETF (560080), indicates a potential shift in investment style, with increasing capital inflow and favorable valuation metrics suggesting a recovery phase ahead for the industry [3][8]. Group 1: Market Performance - On February 2, the Shanghai Composite Index fell by 2.48%, while the Chinese Medicine ETF (560080) experienced a decline of 1.24%, with a total trading volume exceeding 70 million yuan [1]. - The Chinese Medicine ETF has seen continuous capital inflow, accumulating over 100 million yuan in net inflow over the past five days [1][3]. Group 2: Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the Chinese Medicine ETF is 23.96, indicating that the valuation is below 85.61% of the time since its inception in May 2015, highlighting attractive valuation opportunities [3]. - The Chinese medicine sector is perceived to be entering a "sweet spot" in terms of valuation, with a significant portion of stocks showing potential for recovery [3]. Group 3: Individual Stock Performance - Most of the weighted stocks in the Chinese Medicine ETF index closed lower, with notable declines including Jilin Aodong down over 7% and Darentang down over 3% [5]. - Conversely, Dong'e Ejiao was one of the few stocks that rose, gaining over 1% [5]. Group 4: Earnings Forecasts - Jilin Aodong has projected a net profit of approximately 2.265 to 2.482 billion yuan for 2025, representing a year-on-year growth of 46.0% to 60.0%, attributed to increased fair value changes and investment income [7]. - As of January 31, 11 companies within the Chinese Medicine ETF index have released earnings forecasts, with six reporting positive year-on-year growth [7]. Group 5: Future Outlook - The Chinese medicine sector is expected to experience a rebound in 2026, driven by inventory digestion and an anticipated increase in flu incidence in Q4 2025, which may enhance sales of related OTC products [8]. - The potential update of the essential drug catalog is also seen as a catalyst for growth, with companies that can meet the new criteria likely to benefit [8]. Group 6: Investment Themes - Three main investment themes have been identified for the Chinese medicine industry: price governance, consumption recovery, and state-owned enterprise reform [9][10][11]. - The focus on price governance suggests that companies with competitive advantages may benefit from price reductions leading to increased market share [9]. - The recovery of consumer demand, driven by macroeconomic improvement and an aging population, is expected to support sales growth in the Chinese medicine sector [10]. - State-owned enterprises in the industry are anticipated to present investment opportunities as reforms aim to enhance efficiency and performance [11].

Investment Rating - The industry maintains an "Overweight" rating [9] Core Views - The report highlights the performance of the traditional Chinese medicine (TCM) sector, noting a 0.89% increase in the TCM II index, making it the second-best performing sub-sector in the pharmaceutical industry [3] - The report emphasizes the importance of the 2025 performance outlook and the progress of the essential drug catalog adjustments, with many companies showing positive profit growth [6] - The report suggests that the TCM industry may continue to experience structural differentiation, with companies focusing on external markets and innovation to find new growth points [6] Market Performance - The TCM II index closed at 6406.83 points, up 0.89% for the week, while the overall pharmaceutical index fell by 0.39% [3] - The best-performing companies in the TCM sector included *ST Changyao, ST Xiangxue, and Fangsheng Pharmaceutical, while the worst performers included Zhenbaodao and Pianzaihuang [3] Valuation - The TCM sector's PE (ttm) was 27.34X, up 0.23X week-on-week, with a PB (lf) of 2.3X, also showing a slight increase [4] - The PE is at the 28.89% percentile since 2013, while the PB is at the 5.74% percentile [4] Raw Material Market - The TCM raw material index rose by 1.1% due to increased demand for tonic herbs and price hikes in certain materials [5] - The overall market for TCM materials remains volatile, with a notable increase in demand for tonic herbs [5] Investment Suggestions - The report recommends focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [7] - Specific investment targets include companies with strong R&D capabilities, those less affected by centralized procurement, and brands with strong market presence [13]

Investment Rating - The industry maintains a "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [6]. Core Insights - The Chinese medicine sector experienced a decline of 1% last week, with the overall pharmaceutical and biological index down by 0.68%. The only sub-sector to record positive returns was medical services, which rose by 3.29% [2]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is currently at 27.11X, a decrease of 0.28X week-on-week, while the price-to-book (PB) ratio stands at 2.28X, down by 0.02X. These ratios indicate that the sector is within the 28.25% and 5.37% percentiles since 2013, respectively [3]. - The market for traditional Chinese medicine materials is experiencing reduced traffic, with a downward trend expected throughout 2025 due to supply expansion leading to a mismatch in supply and demand. The overall price index for traditional Chinese medicine materials fell by 29.31 points from the beginning to the end of 2025 [4]. - The adjustment of the essential drug list is anticipated to make significant progress in 2026, enhancing the accessibility of grassroots medications and potentially expanding the market rapidly [5]. Summary by Sections Market Performance - The Chinese medicine sector's index closed at 6350.32 points, reflecting a 1% decline last week. In comparison, the chemical pharmaceuticals and biological products sectors also saw declines of 2.4% and 1.21%, respectively [2][12]. Valuation - The current PE ratio for the Chinese medicine sector is 27.11X, with a year-high of 30.26X and a year-low of 24.72X. The PB ratio is 2.28X, with a maximum of 2.52X and a minimum of 2.17X over the past year [3]. Supply Chain Insights - The market for traditional Chinese medicine materials is currently facing a decrease in traffic, with a price index showing a downward trend. The overall price index for 2025 is expected to reflect a decline due to previous overproduction [4]. Policy Developments - The essential drug list has not been updated since 2018, but significant adjustments are expected in 2026, which may enhance the synergy between the essential drug list and medical insurance policies [5]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform. Companies with strong R&D capabilities and unique products are highlighted as potential investment opportunities [6][10].

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [5]. Core Insights - The market performance for the Chinese medicine sector showed a slight decline of 1.67% last week, which is relatively smaller compared to other pharmaceutical segments [1]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is reported at 26.63X, with a slight decrease of 0.45X week-on-week, indicating a valuation within the historical range [2]. - The demand for tonic herbs continues to grow, leading to a slight increase in the Chinese medicinal herb price index, which rose by 0.1% last week [3]. - The integration of Chinese medicinal pieces into a national drug traceability code system is accelerating, which is expected to enhance the quality and management of the industry [4]. Summary by Sections Market Performance - The Chinese medicine sector index closed at 6234.32 points, down 1.67% last week, while the overall pharmaceutical sector index fell by 2.06% [1][11]. - Notable companies with strong performance include Wanbangde, Tianmu Pharmaceutical, and Guhang Medicine, while underperformers include *ST Changyao and ST Hulahua [1][17]. Valuation - The current PE ratio for the Chinese medicine sector is 26.63X, with a year-to-date maximum of 30.26X and a minimum of 24.72X [2]. - The price-to-book (PB) ratio stands at 2.24X, with a year-to-date maximum of 2.52X and a minimum of 2.17X [2]. Industry Trends - The demand for tonic herbs is on the rise, contributing to a slight increase in the price index for Chinese medicinal herbs [3]. - The national drug traceability system for Chinese medicinal pieces is being implemented, which is expected to improve the quality and traceability of medicinal materials [4]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [5]. - Specific investment targets include companies with strong R&D capabilities, unique products, and those less affected by price reductions due to centralized procurement [9].

Core Viewpoint - The release of the "Internet Platform Pricing Behavior Rules" marks a significant step towards institutionalizing and refining price governance in China's platform economy, aiming to protect the rights of consumers and operators while promoting a healthy market environment [3]. Group 1: Regulatory Framework - The National Development and Reform Commission (NDRC), the State Administration for Market Regulation, and the National Internet Information Office have established a regular price supervision mechanism to regulate pricing behaviors on internet platforms [1]. - The rules were modified based on public feedback collected from August 23 to September 22, focusing on standardizing pricing behaviors and enhancing transparency [2]. Group 2: Key Provisions - The rules specify that platform operators must not impose unreasonable restrictions on the pricing behaviors of operators within the platform, thereby protecting their right to set prices autonomously [2][4]. - Operators are required to clearly display pricing information, including dynamic pricing and differential pricing, and to regulate promotional activities to prevent misleading practices [4][5]. - The rules prohibit unfair pricing practices such as predatory pricing, price discrimination, collusion, and price fraud, ensuring a fair competitive environment [4][5]. Group 3: Consumer Protection - The rules mandate that operators must provide clear options for services like automatic renewals and one-click cancellations, ensuring consumers are well-informed and can easily opt out of unwanted charges [4][5]. - There is an emphasis on protecting consumer rights by enforcing transparent pricing and promoting the establishment of online dispute resolution mechanisms [4][6]. Group 4: Implementation and Compliance - The rules will take effect on April 10 of the following year, with platforms required to conduct self-assessments against the regulatory requirements before implementation [6]. - The NDRC emphasizes the need for platform operators to refine their internal compliance systems in line with the new rules, particularly regarding consumer price rights and the autonomy of platform operators [7]. Group 5: Collaborative Governance - Effective implementation of the rules requires collaboration among government, platforms, industries, and society to create a cooperative governance framework [8]. - Platforms are encouraged to shift from passive compliance to proactive governance, enhancing internal management and establishing clear channels for price complaints [8].

Macro Strategy - In October, industrial enterprise profits showed a significant decline, with a year-on-year drop from 21.60% in September to -5.5% in October, leading to a cumulative year-on-year growth rate decrease from 3.20% to 1.90% [2] - The A-share market experienced a rebound from November 24 to November 28, with major indices such as the Shanghai Composite Index rising by 1.40% and the ChiNext Index increasing by 4.54% [3][4] - The rebound in A-shares was attributed to a reversal in the market's previous downward momentum, driven by a shift in expectations regarding the Federal Reserve's interest rate decisions and a recovery in the technology sector [3][4] Industry and Company Analysis Traditional Chinese Medicine Industry - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 1.29% last week, the smallest among secondary sub-sectors in the pharmaceutical industry [9] - The price index for TCM materials showed a slight increase of 0.4%, indicating a recovery in market conditions and improved investor sentiment [12] - Multiple regions have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive market structure [13] Investment Recommendations - The report maintains an "overweight" rating for the TCM industry, suggesting three main investment themes: 1. Price governance, focusing on companies with strong R&D capabilities and unique products that can benefit from price reductions [15] 2. Consumption recovery, driven by macroeconomic improvement and increased health awareness among the aging population, favoring leading TCM brands [16] 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [16] - Recommended stocks include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on companies with strong R&D capabilities and unique products [16]

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [5]. Core Insights - The demand for respiratory medications is expected to rise due to the increase in flu cases, with a reported 955 flu-like illness outbreaks, marking a 53.8% increase from the previous week [4]. - The market performance of the Traditional Chinese Medicine (TCM) sector showed a decline of 6.46% last week, ranking second among secondary pharmaceutical sectors [1]. - The TCM sector's Price-to-Earnings (PE) ratio (ttm) is 27.36X, down by 1.89X week-on-week, while the Price-to-Book (PB) ratio (lf) is 2.31X, down by 0.16X [2]. Market Performance - The TCM sector reported a closing index of 6419.16 points, down 6.46% for the week, while the overall pharmaceutical sector index fell by 6.88% [1][16]. - Among companies, *ST Changyao, Weikang Pharmaceutical, Jiangzhong Pharmaceutical, Yunnan Baiyao, and Dong'e Ejiao showed better performance, while Te Yi Pharmaceutical, Panlong Pharmaceutical, Zhendong Pharmaceutical, Yiling Pharmaceutical, and Enwei Pharmaceutical lagged [1]. Valuation Metrics - The TCM sector's PE ratio is at the 28.94% percentile since 2013, while the PB ratio is at the 5.93% percentile, indicating relatively low valuation compared to historical data [2]. Supply Chain Insights - The market for TCM raw materials is currently weak, with a price index of 224.73 points, reflecting a 0.3% decrease due to oversupply and inventory buildup [3]. Investment Recommendations - Three main investment themes are highlighted: 1. Price governance focusing on competitive advantages and innovation capabilities [5]. 2. Consumption recovery driven by macroeconomic improvement and aging population [5]. 3. State-owned enterprise reform, which is expected to enhance efficiency and performance [5]. Target Companies - Recommended companies include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on those with strong R&D capabilities and unique products [9].

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the traditional Chinese medicine sector [6]. Core Insights - The traditional Chinese medicine sector showed resilience with a 0.81% increase in the index, while the broader pharmaceutical sector declined by 2.4% [2]. - The price-to-earnings (PE) ratio for the traditional Chinese medicine sector is 28.11X, reflecting a slight increase, while the price-to-book (PB) ratio stands at 2.37X, also showing a minor rise [3]. - The recent price index for traditional Chinese medicinal materials has increased by 0.2%, indicating a slight upward trend in the market [4]. - The fourth batch of national procurement for traditional Chinese medicine has been announced, including 90 varieties, which presents both challenges and opportunities for production companies [5]. Summary by Sections Market Performance - The traditional Chinese medicine index closed at 6593.95 points, with a weekly increase of 0.81%, contrasting with declines in other pharmaceutical sectors [2][11]. - Notable performers in the sector include ST HuLuWa, DaRenTang, and ZhongSheng Pharmaceutical, while companies like WanBangDe and QiDi Pharmaceutical lagged [2]. Valuation - The PE ratio for the traditional Chinese medicine sector is currently at 28.11X, with a year-to-date maximum of 30.26X and a minimum of 24.72X [3]. - The PB ratio is at 2.37X, with a maximum of 2.59X and a minimum of 2.17X over the past year [3]. Raw Material Prices - The price index for traditional Chinese medicinal materials has shown a slight increase, with 9 categories rising and 3 falling in the past week [4]. Focus on National Procurement - The fourth batch of national procurement includes 90 varieties, with a focus on products that have significant demand and established clinical applications [5]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [6][9]. - Specific recommendations include companies with strong R&D capabilities, those less affected by procurement impacts, and leading brand enterprises in traditional Chinese medicine [9].

Group 1: PPI and Asset Prices - The PPI has stabilized, with a month-on-month change of 0 for the second consecutive month, indicating a potential trend in domestic asset prices[1] - Despite the current international oil price affecting related industries, there is a strong expectation for future easing by the Federal Reserve, supporting prices of commodities like gold and copper[1] - The implementation of anti-involution policies is showing results in key sectors like photovoltaics and new energy, with significant price increases observed post-National Day[1] Group 2: Market Performance - From October 11 to October 18, the CSI 300 index fell by 2.23%, while the Hang Seng Index dropped by 3.97%, and the S&P 500 rose by 1.71%[2] - The 10-year China bond yield increased by 0.41 basis points, while the 10-year US Treasury yield decreased by 3.01 basis points[2] - The US dollar index decreased by 0.27%, and the offshore RMB appreciated by 0.3%[2] Group 3: Inventory and Fund Behavior - The latest oil inventory stands at 44,355 million tons, up by 2.78 million tons from the previous week[3] - The latest week saw a rise in gold ETF holdings to 3,366 million ounces, an increase of 960,000 ounces[3] - The dollar long position increased by 1,541 contracts to 14,032, while the short position decreased by 1,009 contracts to 24,376[3] Group 4: Economic Indicators - Fixed asset investment year-on-year change is at -0.50%[5] - Retail sales year-on-year growth is at 3.00%[5] - Exports year-on-year growth is at 8.30%[5] - M2 growth rate is at 8.40%[5]